Account
08.01.2025
Pricing and Market Access trends: 2025

Our review of the 2024 pricing and market access revealed key challenges facing the pharmaceutical i...

Read more
Webinar
07.11.2024
Protected: Breaking new ground: key learnings from...

There is no excerpt because this is a protected post.

Read more
Publications
15.10.2024
WODC Europe 2024: Comparing And Contrasting Early ...

AUTHORS: Amy Boyers, Solen Monteil, Mariam Bibi OBJECTIVES  Early Access Programmes (EAPs) prov...

Read more
04.10.2024
EU releases draft implementing act on Joint Scient...

The European Commission's 4th implementing act outlines how health tech developers can obtain early ...

Read more
Articles
17.09.2024
Can Real-World Evidence overcome uncertainty in Ra...

We examine how real-world evidence strategies help address uncertainties in rare disease treatments ...

Read more
Articles
10.09.2024
Strategic approaches to achieving HTA approval for...

Achieving HTA approval for orphan drugs requires strategic planning, early engagement, strong eviden...

Read more
News
03.09.2024
World Orphan Drug Congress Europe 2024

We're thrilled to announce our participation at World Orphan Drug Congress Europe 2024 in Barcelona ...

Read more
News
29.08.2024
ISPOR Europe 2024

We're delighted to announce our participation at ISPOR Europe 2024 in Barcelona this November. We'll...

Read more
Publications
22.08.2024
ISPOR Europe 2024: Are companies Ready for the New...

We explore whether pharma and biotech manufacturers are ready for the new EU HTA process and what op...

Read more
Publications
22.08.2024
ISPOR Europe 2024: Alignment of EU HTA and member ...

We examine whether the joint clinical assessment will expedite patient access and influence value pe...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.